Loading
Access to capital is the primary bottleneck for advancing gene therapy due to the high costs and long development timelines.
“the single biggest bottleneck is actually not technological at all it's Financial it's access to Capital”
The All-In Podcast · Sep 2023 · 1 episode · 108K views on this topicExtracted by a model; may misattribute who said what.